Genmab to take at least one new product to phase III in 2021

Genmab is boosting investments in the company's pipeline, and aside from supporting current star candidates, the investments are meant to lead one more product – at least – to late-stage trials, according to CEO Jan van de Winkel.

Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH

Last year, when Genmab presented its annual financial report, the firm predicted that it would need an additional DKK 1bn (USD 163.7m), at least, to spend on its development.

This development has continued at the Danish biotech company. Genmab informs that it expects to add around DKK 2bn to its expenses for 2021, which is estimated to land at around DKK 5.5-5.8bn.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs